A study led by clinician-scientists and scientists from the National Cancer Centre Singapore (NCCS) and A*STAR’s Genome Institute of Singapore (GIS) and funded by the National Research Foundation Singapore (NRF) has discovered unexpected molecular heterogeneity even within the same liver tumors. More than 40% of HCC harbors more than one molecular subtype within the same tumor and in these, the clinical outcomes for the patients are best predicted by the most aggressive subtype.